The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis.

ABSTRACT:

Background

A myositis-specific autoantibody can now be identified in the majority of patients with myositis. They identify homogeneous patient subgroups and are key tools in developing a personalized approach to disease management. There is substantial clinical interest in exploiting myositis autoantibodies as biomarkers, and consequently, a large number of commercial assays have been developed for their detection. These assays are already in widespread clinical use. In order to better understand perceived concerns from the international myositis community in relation to the reliability of these assays and how they are being used, we conducted a survey of international myositis experts, all of whom were members of the International Myositis Assessment and Clinical Studies group.

SUBMITTER: Tansley SL 

PROVIDER: S-EPMC7227250 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature